Back to results
US 2017/0319554 A1Published application
Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
AssigneeCumberland Emerging Technologies, Inc.
InventorsLeo PAVLIV, Martin OGLETREE
Life of this patent
Estimating the term…
Abstract
The present invention is directed to methods of treating hepatorenal syndrome by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof. The present invention is also directed to methods of treating hepatic encephalopathy and cerebral edema by administration of a therapeutically effective amount of a thromboxane A2 receptor antagonist to a patient in need thereof.
Claims17
1-7. (canceled)
A method of preventing or treating hepatorenal syndrome comprising:
- administering to a patient in need thereof a therapeutically effective amount of a [1S-(1α,2α,3α,4α)]-2-[[3-[4-[(Pentylamino) carbonyl]-2-oxazolyl]-7-oxabicyclo[2.2.1]hept-2-yl]methyl]-benzenepropanoic acid (Ifetroban), and pharmaceutically acceptable salts thereof to a patient in need thereof.
(canceled)
(canceled)
15-31. (canceled)
Dependencies are inferred from the claim text.